Instructor

Barry A. Friedman

Barry A. Friedman, Ph.D., is a Senior Consultant in the Biotechnology, Regulatory Compliance, Microbiology and Aseptic Processing arena. From 2000 to 2007, Dr. Friedman was associated with Cambrex Bio Science Baltimore, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, MD. In that capacity as the Director, Quality Control, he managed a multi-shift Department of thirty one individuals involved in Client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity Dr Friedman enjoyed many client and regulatory compliance interactions.

Dr. Friedman has over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness assistance, quality control, sterility assurance, microbiological/analytical validations and fermentation technology. In addition to the associations listed above, other associations have included Chesapeake Biological Laboratories, W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide.

Dr. Friedman is a frequent seminar and webinar speaker and specializes in the areas of regulatory compliance, internal auditing, aseptic processing for sterile drug products, USP and Warning Letter “dissection”, multi-departmental interactions, validations and the requirements for the manufacture of Phase 1, 2 and 3 clinical trial materials. He has recently given presentations for the FDA, PDA, PTi, TungstenShield, IPA (Canada) and Pharmig (UK). He maintains an active Blog

www.barryafriedmanphdllc.com contains over 200 Blogs that address various Warning Letter and FDA 483 issues as well as over 1,500 “Search” terms. He is a member of ASM, PDA and RAPs. He served as a Captain in the Medical Service Corps, U.S. Army and is the past President and current Treasurer of the Capital Area Chapter, PDA. He recently received the James Agalloco award from PDA which is awarded to a PDA faculty member who exemplifies outstanding performance in education.





Barry A. Friedman: Upcoming and Archived Webinars

  • ECC-669    04/29/2025        upcoming
    MICROBIOLOGY FOR THE NON-MICROBIOLOGIST – AND THE MICROBIOLOGIST WHO DESIRES A GMP MICROBIOLOGICAL REFRESHER
  • ECC-670    04/24/2025        upcoming
    The Microbiology of Water in a GMP Environment
  • ECC-671    04/22/2025        upcoming
    VALIDATION MASTER PLANNING (DEVELOPING A COMPREHENSIVE VALIDATION PACKAGE)
  • ECC-668    03/27/2025        archive
    Risk Management of Raw Materials in a GMP Environment
  • ECC-661    01/29/2025        archive
    Good Laboratory Practices (GLP) vs. Good Manufacturing Practices (GMPs) — A Comparison and Contrast – “Why One Should Use Only GMP Facilities for Manufacturing and Testing”
  • ECC-660    01/22/2025        archive
    Risk Management of Raw Materials in a GMP Environment
  • ECC-659    01/16/2025        archive
    Bioburden Control of Non-Sterile Drug Substances and Products– A New USP General Information Chapter
  • ECC-658    01/15/2025        archive
    Development of a Steam Autoclave Sterilization Validation Plan
  • ECC-654    12/12/2024        archive
    VALIDATION MASTER PLANNING (DEVELOPING A COMPREHENSIVE VALIDATION PACKAGE)
  • ECC-653    12/04/2024        archive
    MICROBIOLOGY FOR THE NON-MICROBIOLOGIST – AND THE MICROBIOLOGIST WHO DESIRES A GMP MICROBIOLOGICAL REFRESHER
  • ECC-652    12/03/2024        archive
    THE BACTERIAL ENDOTOXINS TEST (ISSUES AND SOLUTIONS) TO INCLUDE THE ISSUE OF LOW ENDOTOXIN RECOVERY (LER) AND TR 82 (PDA) AND GENERAL INFORMATION CHAPTER <1085>
  • ECC-648    11/21/2024        archive
    Risk Management and The New General Chapter, USP<60>, Burkholderia cepacia
  • ECC-647    11/19/2024        archive
    Good Laboratory Practices (GLP) vs. Good Manufacturing Practices (GMPs) — A Comparison and Contrast – “Why One Should Use Only GMP Facilities for Manufacturing and Testing”
  • ECC-646    11/14/2024        archive
    Managing Microbiological Out of Specification (OOS) and Out of Trend (OOT) Results in Sterile and Non-Sterile ProductionFDA and ICH Expectations and Guidance
  • ECC-645    11/13/2024        archive
    Risk Management of Raw Materials in a GMP Environment
  • ECC-640    10/29/2024        archive
    The Microbiology of Water in a GMP Environment
  • ECC-639    10/09/2024        archive
    FDA Contract Manufacturing Arrangements for Drugs: Quality Agreements - Their Relationship to Microbiological Issues
  • ECC-638    10/02/2024        archive
    Annual Laboratory Microbiology Training
  • ECC-637    10/01/2024        archive
    Bioburden Control of Non-Sterile Drug Substances and Products– A New USP General Information Chapter
  • ECC-636    09/26/2024        archive
    Process Simulation Testing for Aseptically Filled Products
  • ECC-635    09/24/2024        archive
    VALIDATION MASTER PLANNING (DEVELOPING A COMPREHENSIVE VALIDATION PACKAGE)
  • ECC-633    09/05/2024        archive
    TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE (NEW USP<1222>, November 2019) AND ITS RELATIONSHIP TO THE NEW BRITISH TERMINAL STERILIZATION METHODOLOGY (March 2019)
  • ECC-627    08/27/2024        archive
    Risk Management of Raw Materials in a GMP Environment
  • ECC-624    08/21/2024        archive
    THE BACTERIAL ENDOTOXINS TEST (ISSUES AND SOLUTIONS) TO INCLUDE THE ISSUE OF LOW ENDOTOXIN RECOVERY (LER) AND TR 82 (PDA) AND GENERAL INFORMATION CHAPTER <1085>
  • ECC-626    08/15/2024        archive
    Development of a Steam Autoclave Sterilization Validation Plan


Instructor List